A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sponsored by Bristol-Myers Squibb
About this study
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where this study is enrolling (2)
- Call 402-955-2691
Oncology Hematology West PC
Omaha, Nebraska
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 402-955-2691
Nebraska Cancer Specialists
Grand Island, Nebraska
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.
- ✓Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- ✓Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.
- ✓Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- ✓Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion criteria
- ✕Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.
- ✕Participants must not have prior treatment with immuno-oncology therapies.
- ✕Participants must not have untreated central nervous system (CNS) metastases.
- ✕Other protocol-defined Inclusion/Exclusion criteria apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.